Global Contract Manufacturing Market Analysis
Single User PDF Format: US$ 1,500.00
Multi-User License: US$ 2,200.00
Hard Copy: US$ 1,700.00
CD-ROM: US$ 1,700.00
The global pharmaceutical contract manufacturing industry has registered strong growth during the past few years. The outsourcing of drugs manufacturing provides many advantages to the pharmaceutical companies, such as improved production capacity, quicker time to market drugs, and low scale up cost. With the help of contract manufacturing, pharmaceutical companies will be able to meet growing demand for new drugs and improve their core competencies. All these factors supported the contract manufacturing market to generate revenue worth around US$ 22.5 Billion at the end of 2009.
According to our new research report “Global Contract Manufacturing Market Analysis”, demand for contract manufacturing services has been continuously soaring due to the rising cost pressure on pharmaceutical companies. Besides, the recent global economic slowdown was a major factor for the adoption of the contract manufacturing model. The leading pharma companies in the market are also looking at this model as a means to expand into the biosimilars and generics segments. With the changing economic scenario and the pressure of reducing drugs manufacturing cost, the global contract manufacturing market is expected to grow at a CAGR of around 11% during 2011-2013.
We have also found that countries, such as India, China, Singapore, Russia, and Brazil are considered as the developed markets for contract manufacturers. The economic conditions of these countries are providing immense opportunities to the pharmaceutical manufacturers to expand their businesses. Countries, like Vietnam, South Korea, and Bangladesh are rapidly emerging among other contract manufacturing destinations. Majority of the drugs exported from these countries are destined to the American and European markets. In this regard, our research report provides complete information regarding the export of drugs from these countries.
The report provides an extensive research and prudent analysis of the global contract manufacturing industry. It gives an insight into the current and future market trends. The report has also studied the key contract manufacturers in all the countries to help clients understand the overall market dynamics. The report will work as an investment guide for the clients looking to invest or outsource their manufacturing in these markets.
Multi-User License: US$ 2,200.00
Hard Copy: US$ 1,700.00
CD-ROM: US$ 1,700.00
The global pharmaceutical contract manufacturing industry has registered strong growth during the past few years. The outsourcing of drugs manufacturing provides many advantages to the pharmaceutical companies, such as improved production capacity, quicker time to market drugs, and low scale up cost. With the help of contract manufacturing, pharmaceutical companies will be able to meet growing demand for new drugs and improve their core competencies. All these factors supported the contract manufacturing market to generate revenue worth around US$ 22.5 Billion at the end of 2009.
According to our new research report “Global Contract Manufacturing Market Analysis”, demand for contract manufacturing services has been continuously soaring due to the rising cost pressure on pharmaceutical companies. Besides, the recent global economic slowdown was a major factor for the adoption of the contract manufacturing model. The leading pharma companies in the market are also looking at this model as a means to expand into the biosimilars and generics segments. With the changing economic scenario and the pressure of reducing drugs manufacturing cost, the global contract manufacturing market is expected to grow at a CAGR of around 11% during 2011-2013.
We have also found that countries, such as India, China, Singapore, Russia, and Brazil are considered as the developed markets for contract manufacturers. The economic conditions of these countries are providing immense opportunities to the pharmaceutical manufacturers to expand their businesses. Countries, like Vietnam, South Korea, and Bangladesh are rapidly emerging among other contract manufacturing destinations. Majority of the drugs exported from these countries are destined to the American and European markets. In this regard, our research report provides complete information regarding the export of drugs from these countries.
The report provides an extensive research and prudent analysis of the global contract manufacturing industry. It gives an insight into the current and future market trends. The report has also studied the key contract manufacturers in all the countries to help clients understand the overall market dynamics. The report will work as an investment guide for the clients looking to invest or outsource their manufacturing in these markets.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. KEY MARKET TRENDS
3.1 Asia Dominating Regional Growth
3.2 Bio Manufacturing
3.3 More Focus on Quality Products and GMP Regulations
4. INDUSTRY PERFORMANCE
4.1 Market Size and Growth
4.2 Strategic Initiatives
4.3 Developed Markets
4.3.1 India
4.3.2 Brazil
4.3.3 China
4.3.4 Singapore
4.3.5 Russia
4.3.6 Ukraine
4.4 Developing Markets
4.4.1 Mexico
4.4.2 Vietnam
4.4.3 Bangladesh
4.4.4 Egypt
4.4.5 South Korea
5. CURRENT INDUSTRY ISSUES
5.1 Quality Assurance Risk
5.2 IP Issues
5.3 Impact of Political and Economic Instability
5.4 Inefficient Project Handling and Delivery
6. COMPETITIVE LANDSCAPE
6.1 Catalent Pharma Solutions, Inc.
6.2 Lonza Group Ltd.
6.3 Althea Technologies
6.4 Dishman Pharmaceuticals and Chemicals Ltd.
6.5 Jubilant Life Sciences
6.6 NextPharma
6.7 Wockhardt
2. RESEARCH METHODOLOGY
3. KEY MARKET TRENDS
3.1 Asia Dominating Regional Growth
3.2 Bio Manufacturing
3.3 More Focus on Quality Products and GMP Regulations
4. INDUSTRY PERFORMANCE
4.1 Market Size and Growth
4.2 Strategic Initiatives
4.3 Developed Markets
4.3.1 India
4.3.2 Brazil
4.3.3 China
4.3.4 Singapore
4.3.5 Russia
4.3.6 Ukraine
4.4 Developing Markets
4.4.1 Mexico
4.4.2 Vietnam
4.4.3 Bangladesh
4.4.4 Egypt
4.4.5 South Korea
5. CURRENT INDUSTRY ISSUES
5.1 Quality Assurance Risk
5.2 IP Issues
5.3 Impact of Political and Economic Instability
5.4 Inefficient Project Handling and Delivery
6. COMPETITIVE LANDSCAPE
6.1 Catalent Pharma Solutions, Inc.
6.2 Lonza Group Ltd.
6.3 Althea Technologies
6.4 Dishman Pharmaceuticals and Chemicals Ltd.
6.5 Jubilant Life Sciences
6.6 NextPharma
6.7 Wockhardt
LIST OF FIGURES:
Figure 4-1: Global - Pharma Contract Manufacturing Market (Billion US$), 2009-2013
Figure 4-2: India - Pharma Contract Manufacturing Market (Million US$), 2009-2013
Figure 4-3: India - API Export (Billion US$), 2009-2013
Figure 4-4: China - Finished Drugs Trade (Billion US$), 2009-2013
Figure 4-5: China - API Export (Billion US$), 2008-2013
Figure 4-1: Global - Pharma Contract Manufacturing Market (Billion US$), 2009-2013
Figure 4-2: India - Pharma Contract Manufacturing Market (Million US$), 2009-2013
Figure 4-3: India - API Export (Billion US$), 2009-2013
Figure 4-4: China - Finished Drugs Trade (Billion US$), 2009-2013
Figure 4-5: China - API Export (Billion US$), 2008-2013
LIST OF TABLES:
Table 4-1: India - Key Contract Manufacturers and Their Business Segments
Table 4-2: Brazil - Key Contract Manufacturers and Their Business Segments
Table 4-3: China - Key Contract Manufacturers and Their Business Segments
Table 4-4: Singapore - Key Contract Manufacturers and Their Business Segments
Table 4-5: Russia - Key Contract Manufacturers and Their Business Segments
Table 4-6: Ukraine - Key Contract Manufacturers and Their Business Segments
Table 4-7: Mexico - Key Contract Manufacturers and Their Business Segments
Table 4-8: Vietnam - Key Contract Manufacturers and Their Business Segments
Table 4-9: Bangladesh - Key Contract Manufacturers and Their Business Segments
Table 4-10: Egypt - Key Contract Manufacturers and Their Business Segments
Table 4-11: South Korea - Key Contract Manufacturers and Their Business Segments
Table 6-1: Catalent Pharma Solutions, Inc. - Strengths & Weaknesses
Table 6-2: Lonza Group Ltd. - Strengths & Weaknesses
Table 6-3: Althea Technologies - Strengths & Weaknesses
Table 6-4: Dishman Pharmaceuticals and Chemicals Ltd - Strengths & Weaknesses
Table 6-5: Jubilant Life Sciences Ltd - Strengths & Weaknesses
Table 6-6: NextPharma - Strengths & Weaknesses
Table 6-7: Wockhardt - Strengths & Weaknesses
Table 4-1: India - Key Contract Manufacturers and Their Business Segments
Table 4-2: Brazil - Key Contract Manufacturers and Their Business Segments
Table 4-3: China - Key Contract Manufacturers and Their Business Segments
Table 4-4: Singapore - Key Contract Manufacturers and Their Business Segments
Table 4-5: Russia - Key Contract Manufacturers and Their Business Segments
Table 4-6: Ukraine - Key Contract Manufacturers and Their Business Segments
Table 4-7: Mexico - Key Contract Manufacturers and Their Business Segments
Table 4-8: Vietnam - Key Contract Manufacturers and Their Business Segments
Table 4-9: Bangladesh - Key Contract Manufacturers and Their Business Segments
Table 4-10: Egypt - Key Contract Manufacturers and Their Business Segments
Table 4-11: South Korea - Key Contract Manufacturers and Their Business Segments
Table 6-1: Catalent Pharma Solutions, Inc. - Strengths & Weaknesses
Table 6-2: Lonza Group Ltd. - Strengths & Weaknesses
Table 6-3: Althea Technologies - Strengths & Weaknesses
Table 6-4: Dishman Pharmaceuticals and Chemicals Ltd - Strengths & Weaknesses
Table 6-5: Jubilant Life Sciences Ltd - Strengths & Weaknesses
Table 6-6: NextPharma - Strengths & Weaknesses
Table 6-7: Wockhardt - Strengths & Weaknesses
